Articles tagged with: PAN1

Trial Update

Monday, 04 June 2012 Posted in News, 2012

In exciting developments, three patients have now joined the PAN 1 study. The PAN 1 study aim is to prospectively evaluate hENT1 as a predictive biomarker of benefit from gemcitabine treatment in advanced Pancreatic Cancer. In lay English, this means researchers at the AGITG will test whether hENT1 can show whether an individual patient with advanced Pancreatic Cancer will get benefit from the standard Pancreatic Cancer chemotherapy drug Gemcitabine or not.